Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
Study Warns on Venetoclax in Double-Hit Lymphoma
Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen
www.medpagetoday.com
September 15, 2026 at 2:11 AM
Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.
Read more here ➡️: www.onclive.com/view/pirtobr...
#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Read more here ➡️: www.onclive.com/view/pirtobr...
#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Pirtobrutinib Elicits Responses After Covalent BTK Inhibitor Failure in R/R CLL | OncLive
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
www.onclive.com
September 14, 2026 at 8:45 PM
📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.
Read more here ➡️: www.onclive.com/view/pirtobr...
#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Read more here ➡️: www.onclive.com/view/pirtobr...
#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
This somehow unlocked the memory of Mike asking Okung on a really early episode of the Real Rob Report what BDR stood for in his Twitter handle BDR76. Anyway I believe in BCL2.
September 14, 2026 at 1:49 AM
This somehow unlocked the memory of Mike asking Okung on a really early episode of the Real Rob Report what BDR stood for in his Twitter handle BDR76. Anyway I believe in BCL2.
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
September 10, 2026 at 7:52 PM
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
September 10, 2026 at 7:52 PM
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
With sonrotoclax now the first BCL2 inhibitor approved in MCL, @LymphClinician of @cityofhope breaks down where the agent fits in the relapsed/refractory treatment paradigm #lymsm #oncology www.onclive.com/view/sonroto...
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL | OncLive
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
www.onclive.com
September 4, 2026 at 1:11 PM
With sonrotoclax now the first BCL2 inhibitor approved in MCL, @LymphClinician of @cityofhope breaks down where the agent fits in the relapsed/refractory treatment paradigm #lymsm #oncology www.onclive.com/view/sonroto...
Intermembrane coupling between Bcl-xL and the IP3 receptor supports local Ca2+ transfer at ER-mitochondrial contacts
Intermembrane coupling between Bcl-xL and the IP3 receptor supports local Ca2+ transfer at ER-mitochondrial contacts
Ghosh et al. report that the anti-apoptotic Bcl2 family protein, Bcl-xL, primarily found in the outer mitochondrial membrane, interacts with endoplasmic reticulum resident protein inositol 1,4,5-trisphosphate receptors. This interaction facilitates local calcium transfer at the ER-mitochondria contacts but does not impact mitochondrial calcium transfer due to global changes in cellular calcium.
dlvr.it
August 25, 2026 at 7:50 PM
Intermembrane coupling between Bcl-xL and the IP3 receptor supports local Ca2+ transfer at ER-mitochondrial contacts
#LegacyContent: Comparison of the Mutational Profile between BCL2- and BCL6-Rearrangement Positive Follicular Lymphoma. @cniostopcancer.bsky.social @idibaps.bsky.social
Free in the #OpenArchive: https://loom.ly/U7X9p0g
Free in the #OpenArchive: https://loom.ly/U7X9p0g
Comparison of the Mutational Profile between BCL2- and BCL6-Rearrangement Positive Follicular Lymphoma
It was recently reported that follicular lymphoma (FL) with BCL6 rearrangement (R)
is associated with favorable progression-free survival, whereas BCL2-R and BCL2-6-R
cases are associated with disease progression. However, the pathologic mechanism remained
unexplored. This study analyzed the mutational landscape and immune microenvironment
of 31 FL cases, including 16 BCL2-R, 11 BCL6-R, and 4 BCL2-6-R FL cases. The method
included an in-house next-generation targeted sequencing panel of 168 g...
www.jmdjournal.org
August 14, 2026 at 7:01 PM
#LegacyContent: Comparison of the Mutational Profile between BCL2- and BCL6-Rearrangement Positive Follicular Lymphoma. @cniostopcancer.bsky.social @idibaps.bsky.social
Free in the #OpenArchive: https://loom.ly/U7X9p0g
Free in the #OpenArchive: https://loom.ly/U7X9p0g
🚀Today’s questions!
Swipe to see the answers and explanations!
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #Polatuzumab #PolaRCHP #Lymphoma #Hematology #HemeOnc #Oncology #ClinicalHematology #MedicalEducation #MedEd #HemeHub
Swipe to see the answers and explanations!
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #Polatuzumab #PolaRCHP #Lymphoma #Hematology #HemeOnc #Oncology #ClinicalHematology #MedicalEducation #MedEd #HemeHub
August 11, 2026 at 2:48 AM
🚀Today’s questions!
Swipe to see the answers and explanations!
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #Polatuzumab #PolaRCHP #Lymphoma #Hematology #HemeOnc #Oncology #ClinicalHematology #MedicalEducation #MedEd #HemeHub
Swipe to see the answers and explanations!
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #Polatuzumab #PolaRCHP #Lymphoma #Hematology #HemeOnc #Oncology #ClinicalHematology #MedicalEducation #MedEd #HemeHub
🩸 Facts about Diffuse Large B-Cell Lymphoma:
MYC rearrangements, double-hit/triple-hit lymphoma, double expressor status, CD5+ DLBCL, and genetic subtypes that further refine prognosis.
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #BCL6 #Oncology #ClinicalHematology #HemeHub
MYC rearrangements, double-hit/triple-hit lymphoma, double expressor status, CD5+ DLBCL, and genetic subtypes that further refine prognosis.
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #BCL6 #Oncology #ClinicalHematology #HemeHub
August 11, 2026 at 2:43 AM
🩸 Facts about Diffuse Large B-Cell Lymphoma:
MYC rearrangements, double-hit/triple-hit lymphoma, double expressor status, CD5+ DLBCL, and genetic subtypes that further refine prognosis.
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #BCL6 #Oncology #ClinicalHematology #HemeHub
MYC rearrangements, double-hit/triple-hit lymphoma, double expressor status, CD5+ DLBCL, and genetic subtypes that further refine prognosis.
#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #BCL6 #Oncology #ClinicalHematology #HemeHub
Correlation isn't causation, so we tested it 3 independent ways: genetic depletion of p16-hi cells (p16-3MR mice), the BCL2/BCLxL-targeted ABT-263, and senolytics dasatinib + quercetin. All three depleted senescent MSCs and shrank Dnmt3a-mutant chimerism in vivo.
August 6, 2026 at 11:58 AM
Correlation isn't causation, so we tested it 3 independent ways: genetic depletion of p16-hi cells (p16-3MR mice), the BCL2/BCLxL-targeted ABT-263, and senolytics dasatinib + quercetin. All three depleted senescent MSCs and shrank Dnmt3a-mutant chimerism in vivo.
DLBCL 的 double-hit 屬於 GCB
MYC 加 BCL2 易位的 high-grade B-cell lymphoma 幾乎都出現在 GCB 型，不是 ABC 型 —— 因為 BCL2 易位 t(14;18) 本身就是生發中心來源的標記。
其餘三句正確：GCB 預後優於 ABC；ABC 靠 BCR 與 NF-κB 訊號存活；EZH2 突變富集於 GCB。
#血液專科
https://hema-2026.hsiehting.com/q/110-100
MYC 加 BCL2 易位的 high-grade B-cell lymphoma 幾乎都出現在 GCB 型，不是 ABC 型 —— 因為 BCL2 易位 t(14;18) 本身就是生發中心來源的標記。
其餘三句正確：GCB 預後優於 ABC；ABC 靠 BCR 與 NF-κB 訊號存活；EZH2 突變富集於 GCB。
#血液專科
https://hema-2026.hsiehting.com/q/110-100
August 4, 2026 at 8:07 AM
DLBCL 的 double-hit 屬於 GCB
MYC 加 BCL2 易位的 high-grade B-cell lymphoma 幾乎都出現在 GCB 型，不是 ABC 型 —— 因為 BCL2 易位 t(14;18) 本身就是生發中心來源的標記。
其餘三句正確：GCB 預後優於 ABC；ABC 靠 BCR 與 NF-κB 訊號存活；EZH2 突變富集於 GCB。
#血液專科
https://hema-2026.hsiehting.com/q/110-100
MYC 加 BCL2 易位的 high-grade B-cell lymphoma 幾乎都出現在 GCB 型，不是 ABC 型 —— 因為 BCL2 易位 t(14;18) 本身就是生發中心來源的標記。
其餘三句正確：GCB 預後優於 ABC；ABC 靠 BCR 與 NF-κB 訊號存活；EZH2 突變富集於 GCB。
#血液專科
https://hema-2026.hsiehting.com/q/110-100
A paper using RRID:AB_11042766 from @proteintech.bsky.social was just published in Cell Chemical Biology. RRIDs improve reproducibility in scientific research. #OpenScience #accelerateopenscience #reproducibility
Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer
Read the full paper: Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer
doi.org
August 4, 2026 at 7:00 AM
A paper using RRID:AB_11042766 from @proteintech.bsky.social was just published in Cell Chemical Biology. RRIDs improve reproducibility in scientific research. #OpenScience #accelerateopenscience #reproducibility
SMZL 的陰性組合才是關鍵
陽性：CD19、CD20、CD22、CD79a、FMC7、sIgM、BCL2（非特異）。
陰性：CD5、CD10、CD23、CD43、CD103、cyclin D1、BCL6。
記法：Spleen big、Marginal、Zero nodes、Villous —— 脾大、無淋巴結腫大、周邊血絨毛狀淋巴球。
#血液專科
https://hema-2026.hsiehting.com/q/111-031
陽性：CD19、CD20、CD22、CD79a、FMC7、sIgM、BCL2（非特異）。
陰性：CD5、CD10、CD23、CD43、CD103、cyclin D1、BCL6。
記法：Spleen big、Marginal、Zero nodes、Villous —— 脾大、無淋巴結腫大、周邊血絨毛狀淋巴球。
#血液專科
https://hema-2026.hsiehting.com/q/111-031
August 4, 2026 at 3:25 AM
SMZL 的陰性組合才是關鍵
陽性：CD19、CD20、CD22、CD79a、FMC7、sIgM、BCL2（非特異）。
陰性：CD5、CD10、CD23、CD43、CD103、cyclin D1、BCL6。
記法：Spleen big、Marginal、Zero nodes、Villous —— 脾大、無淋巴結腫大、周邊血絨毛狀淋巴球。
#血液專科
https://hema-2026.hsiehting.com/q/111-031
陽性：CD19、CD20、CD22、CD79a、FMC7、sIgM、BCL2（非特異）。
陰性：CD5、CD10、CD23、CD43、CD103、cyclin D1、BCL6。
記法：Spleen big、Marginal、Zero nodes、Villous —— 脾大、無淋巴結腫大、周邊血絨毛狀淋巴球。
#血液專科
https://hema-2026.hsiehting.com/q/111-031
同樣是 t(14;18) 意義卻不同
在 FL：t(14;18)(q32;q21) 是 IGH-BCL2。
在 MALT lymphoma：同一個座標卻是 IGH-MALT1，好發腮腺、結膜等非胃腸道部位。
斷點相同但融合基因完全不同，這是最容易被混淆的一組。
其他 MALT 轉位：t(1;14) BCL10-IGH、t(3;14) FOXP1-IGH。
#血液專科
https://hema-2026.hsiehting.com/q/113-048
在 FL：t(14;18)(q32;q21) 是 IGH-BCL2。
在 MALT lymphoma：同一個座標卻是 IGH-MALT1，好發腮腺、結膜等非胃腸道部位。
斷點相同但融合基因完全不同，這是最容易被混淆的一組。
其他 MALT 轉位：t(1;14) BCL10-IGH、t(3;14) FOXP1-IGH。
#血液專科
https://hema-2026.hsiehting.com/q/113-048
August 3, 2026 at 1:12 PM
同樣是 t(14;18) 意義卻不同
在 FL：t(14;18)(q32;q21) 是 IGH-BCL2。
在 MALT lymphoma：同一個座標卻是 IGH-MALT1，好發腮腺、結膜等非胃腸道部位。
斷點相同但融合基因完全不同，這是最容易被混淆的一組。
其他 MALT 轉位：t(1;14) BCL10-IGH、t(3;14) FOXP1-IGH。
#血液專科
https://hema-2026.hsiehting.com/q/113-048
在 FL：t(14;18)(q32;q21) 是 IGH-BCL2。
在 MALT lymphoma：同一個座標卻是 IGH-MALT1，好發腮腺、結膜等非胃腸道部位。
斷點相同但融合基因完全不同，這是最容易被混淆的一組。
其他 MALT 轉位：t(1;14) BCL10-IGH、t(3;14) FOXP1-IGH。
#血液專科
https://hema-2026.hsiehting.com/q/113-048
NHL 的招牌轉位
MCL：t(11;14)(q13;q32)，CCND1 並置到 IGH，>95%
FL：t(14;18)(q32;q21)，BCL2 並置到 IGH，80–90%
Burkitt：t(8;14)(q24;q32) MYC-IGH 最常見，variant 有 t(2;8)、t(8;22)
T-PLL：inv(14)(q11q32) 或 t(14;14)，約 75%
#血液專科
https://hema-2026.hsiehting.com/q/113-042
MCL：t(11;14)(q13;q32)，CCND1 並置到 IGH，>95%
FL：t(14;18)(q32;q21)，BCL2 並置到 IGH，80–90%
Burkitt：t(8;14)(q24;q32) MYC-IGH 最常見，variant 有 t(2;8)、t(8;22)
T-PLL：inv(14)(q11q32) 或 t(14;14)，約 75%
#血液專科
https://hema-2026.hsiehting.com/q/113-042
August 3, 2026 at 1:00 PM
NHL 的招牌轉位
MCL：t(11;14)(q13;q32)，CCND1 並置到 IGH，>95%
FL：t(14;18)(q32;q21)，BCL2 並置到 IGH，80–90%
Burkitt：t(8;14)(q24;q32) MYC-IGH 最常見，variant 有 t(2;8)、t(8;22)
T-PLL：inv(14)(q11q32) 或 t(14;14)，約 75%
#血液專科
https://hema-2026.hsiehting.com/q/113-042
MCL：t(11;14)(q13;q32)，CCND1 並置到 IGH，>95%
FL：t(14;18)(q32;q21)，BCL2 並置到 IGH，80–90%
Burkitt：t(8;14)(q24;q32) MYC-IGH 最常見，variant 有 t(2;8)、t(8;22)
T-PLL：inv(14)(q11q32) 或 t(14;14)，約 75%
#血液專科
https://hema-2026.hsiehting.com/q/113-042
幾組必記的 lymphoma 分子配對
Classical HCL：BRAF V600E，98–100%
Double/triple-hit lymphoma：MYC 加 BCL2 或 BCL6 易位
MALT lymphoma：t(11;18) 最常見於胃、腸、肺
LPL/WM：MYD88 L265P
SMZL：NOTCH2、KLF2、del(7q)
#血液專科
https://hema-2026.hsiehting.com/q/113-010
Classical HCL：BRAF V600E，98–100%
Double/triple-hit lymphoma：MYC 加 BCL2 或 BCL6 易位
MALT lymphoma：t(11;18) 最常見於胃、腸、肺
LPL/WM：MYD88 L265P
SMZL：NOTCH2、KLF2、del(7q)
#血液專科
https://hema-2026.hsiehting.com/q/113-010
August 3, 2026 at 11:46 AM
幾組必記的 lymphoma 分子配對
Classical HCL：BRAF V600E，98–100%
Double/triple-hit lymphoma：MYC 加 BCL2 或 BCL6 易位
MALT lymphoma：t(11;18) 最常見於胃、腸、肺
LPL/WM：MYD88 L265P
SMZL：NOTCH2、KLF2、del(7q)
#血液專科
https://hema-2026.hsiehting.com/q/113-010
Classical HCL：BRAF V600E，98–100%
Double/triple-hit lymphoma：MYC 加 BCL2 或 BCL6 易位
MALT lymphoma：t(11;18) 最常見於胃、腸、肺
LPL/WM：MYD88 L265P
SMZL：NOTCH2、KLF2、del(7q)
#血液專科
https://hema-2026.hsiehting.com/q/113-010
FL 的定位
它是西方第二常見的 NHL，排在 DLBCL 之後；準確的說法是「最常見的 indolent B-cell lymphoma」。
t(14;18) 讓 BCL2 過度表現，走的是抗凋亡而非促增生 —— 這解釋了它為何惰性卻難根治。
#血液專科
https://hema-2026.hsiehting.com/q/114-054
它是西方第二常見的 NHL，排在 DLBCL 之後；準確的說法是「最常見的 indolent B-cell lymphoma」。
t(14;18) 讓 BCL2 過度表現，走的是抗凋亡而非促增生 —— 這解釋了它為何惰性卻難根治。
#血液專科
https://hema-2026.hsiehting.com/q/114-054
August 3, 2026 at 9:18 AM
FL 的定位
它是西方第二常見的 NHL，排在 DLBCL 之後；準確的說法是「最常見的 indolent B-cell lymphoma」。
t(14;18) 讓 BCL2 過度表現，走的是抗凋亡而非促增生 —— 這解釋了它為何惰性卻難根治。
#血液專科
https://hema-2026.hsiehting.com/q/114-054
它是西方第二常見的 NHL，排在 DLBCL 之後；準確的說法是「最常見的 indolent B-cell lymphoma」。
t(14;18) 讓 BCL2 過度表現，走的是抗凋亡而非促增生 —— 這解釋了它為何惰性卻難根治。
#血液專科
https://hema-2026.hsiehting.com/q/114-054
Online now! Online now! Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer #chembiol
Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer
Drug repurposing can uncover unexpected therapeutic opportunities in cancer. Li et al. identify the antiviral drug simeprevir as an inhibitor of KPNB1-mediated NF-κB signaling, uncovering a KPNB1-p65-BCL2 survival axis and establishing simeprevir as a promising therapeutic lead.
dlvr.it
July 31, 2026 at 3:30 PM
Online now! Online now! Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer #chembiol
El CIC identifica cómo frenar la resistencia a la quimioterapia
Un estudio dirigido por Javier Vaquero demuestra en modelos experimentales que los fibroblastos del entorno tumoral protegen al cáncer de vías biliares intrahepático y plantea bloquear la proteína BCL2 para recuperar la sensibilidad…
Un estudio dirigido por Javier Vaquero demuestra en modelos experimentales que los fibroblastos del entorno tumoral protegen al cáncer de vías biliares intrahepático y plantea bloquear la proteína BCL2 para recuperar la sensibilidad…
El CIC identifica cómo frenar la resistencia a la quimioterapia
Un estudio dirigido por Javier Vaquero demuestra en modelos experimentales que los fibroblastos del entorno tumoral protegen al cáncer de vías biliares intrahepático y plantea bloquear la proteína BCL2 para recuperar la sensibilidad al tratamiento. Un equipo del Centro de Investigación del Cáncer de Salamanca ha identificado un mecanismo por el que determinadas células que rodean al cáncer de vías biliares intrahepático reducen la eficacia de la quimioterapia y ha probado una estrategia experimental para debilitar esa protección.
gacetadecastillayleon.com
July 29, 2026 at 6:16 AM
El CIC identifica cómo frenar la resistencia a la quimioterapia
Un estudio dirigido por Javier Vaquero demuestra en modelos experimentales que los fibroblastos del entorno tumoral protegen al cáncer de vías biliares intrahepático y plantea bloquear la proteína BCL2 para recuperar la sensibilidad…
Un estudio dirigido por Javier Vaquero demuestra en modelos experimentales que los fibroblastos del entorno tumoral protegen al cáncer de vías biliares intrahepático y plantea bloquear la proteína BCL2 para recuperar la sensibilidad…
💥Evaluating the Protective Effect of Melatonin on Apoptosis, Expression of Bax and Bcl2 Genes, and ROS Level after Radiofrequency Radiation on L929 Fibroblast Cell Line
jbpe.sums.ac.ir/article_5151...
jbpe.sums.ac.ir/article_5151...
jbpe.sums.ac.ir
July 28, 2026 at 7:54 AM
💥Evaluating the Protective Effect of Melatonin on Apoptosis, Expression of Bax and Bcl2 Genes, and ROS Level after Radiofrequency Radiation on L929 Fibroblast Cell Line
jbpe.sums.ac.ir/article_5151...
jbpe.sums.ac.ir/article_5151...
Our collaborative study on mechanisms of venetoclax resistance by BCL-2 mutations is now published in #Advanced #Science journal. Please check LinkedIn for a more detailed explanation and gratitude to all contributors, collaborators and funders.
advanced.onlinelibrary.wiley.com/doi/10.1002/...
advanced.onlinelibrary.wiley.com/doi/10.1002/...
Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL-2 variants. G101V and D103Y reduce d...
advanced.onlinelibrary.wiley.com
July 27, 2026 at 10:09 PM
Our collaborative study on mechanisms of venetoclax resistance by BCL-2 mutations is now published in #Advanced #Science journal. Please check LinkedIn for a more detailed explanation and gratitude to all contributors, collaborators and funders.
advanced.onlinelibrary.wiley.com/doi/10.1002/...
advanced.onlinelibrary.wiley.com/doi/10.1002/...
Importantly, this mutation confers a profound fitness disadvantage in the absence of selection pressure from BTK-targeting agents & co-treatment with BCL2 inhibitors mitigates the expansion of BTK A428D in the setting of BTK degrader treatment:
July 22, 2026 at 2:11 PM
Importantly, this mutation confers a profound fitness disadvantage in the absence of selection pressure from BTK-targeting agents & co-treatment with BCL2 inhibitors mitigates the expansion of BTK A428D in the setting of BTK degrader treatment:
Lithium, used 25+ years, could modify dementia. Works by boosting Bcl2, BDNF, inhibiting GSK3β, not just fixing amyloid or tau. PMID:42268602, JAMA Psychiatry 2026, @JAMAPsych https://doi.org/10.1001/jamapsychiatry.2026.1296 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1001/jamapsychiatry.2026.1296
No description available
doi.org
July 20, 2026 at 7:00 PM
How specific structural differences of Bcl2 proteins modulate the interaction with BH3 domains and apoptotic function https://www.biorxiv.org/content/10.64898/2026.07.17.739112v1
July 17, 2026 at 9:53 PM
How specific structural differences of Bcl2 proteins modulate the interaction with BH3 domains and apoptotic function https://www.biorxiv.org/content/10.64898/2026.07.17.739112v1